more

Deciphera Pharmaceuticals, Inc. (DCPH)

(Delayed Data from NSDQ)

$23.59 USD

+0.67 (2.92%)

Updated May 3, 2019 04:00 PM ET

After-Market: $23.47 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on March 09,2020

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -15.93% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

DCPHPositive Net Change

Deciphera's NDA for GIST Drug Gets Priority Review From FDA

by Zacks Equity Research Published on February 13,2020

The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.

biotechs

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on November 04,2019

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -7.56% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

DCPHPositive Net Change

What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?

by Zacks Equity Research Published on October 30,2019

Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.

medical

Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?

by Zacks Equity Research Published on October 17,2019

Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.

Deciphera Pharmaceuticals, Inc. (DCPH) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research Published on October 04,2019

Deciphera Pharmaceuticals, Inc. (DCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

DCPHPositive Net Change

Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%

by Zacks Equity Research Published on August 14,2019

Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.